Navigation Links
CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
Date:2/22/2010

CEL-2000, administered after disease (RA) symptoms had started, prevented, in a statistically significant manner, the further development  of arthritic conditions, including joint swelling and deformation, bone and cartilage changes and was accompanied by serum cytokine alterations over the CEL-2000 treatment period with comparable or better activity than the well accepted etanercept (Enbrel®) therapy.  The mode of action is very consistent with the findings of induction of IL-12 followed by interferon gamma and an inhibition of TNF-alpha and IL-17 production. TNF-alpha and IL-17 are both key cytokines for induction of the pathology seen in rheumatoid arthritis and TNF-alpha is the target of many current RA therapies such as Enbrel, Remicaid, and Humaria.  The protection effect mediated by CEL-2000 treatment against RA was also demonstrated histologically with significant reductions in:   1) inflammation, 2) cartilage destruction, 3) bone resorption, and 4) pannus membrane formation in the synovial space compared to untreated controls.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "These experimental results were achieved through a reduction of the inflammatory response that is known to attack the patients' joints.  The mode of action of CEL-2000 in RA appears to be similar to our new investigational therapy for H1N1 hospitalized patients, as it attempts to avoid the excess TNF-alpha and other pro-inflammatory cytokines.  We feel that this new data is encouraging both for this rheumatoid arthritis vaccine as well as in support of our H1N1 treatment currently under develop
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
3. CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
4. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
5. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
6. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
9. CEL-SCI Expands H1N1 Flu Virus Work
10. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
11. CEL-SCI Posts New Corporate Presentation to Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Pharma ... new infographic summary of the results from an ... third of all respondents stated that CROs would be an ... of respondents will be running 6 or more clinical trials ... the Clinical Trial Supply USA Summit ...
(Date:6/18/2013)... 19, 2013 , Safinamide ... (PD) patients as add-on to levodopa ... motor symptoms in fluctuating PD patients as add-on ... Pharmaceuticals S.p.A. ("Newron"), a research and development company ... its partner Zambon S.p.A., a pharmaceutical company strongly ...
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... priced its previously announced public offering of common shares ... issue 23,529,412 common shares at a price of $85.00 ... billion. The Company will file a final prospectus supplement ... and will make a similar filing with the securities ...
Breaking Medicine Technology:Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... 13, 2011 Champions Oncology, Inc. formerly Champions Biotechnology, ... Fiscal Year 2012 First Quarter Financial Results:Total operating ... $1.63 million compared to $1.60 million in the first ... first quarter of fiscal 2012 were $3.85 million compared ...
... Sept. 13, 2011 IMD Companies, Inc., (OTC Markets ... The company acquired the brand from Healthy America Inc., ... April 25, 2011 following a vote of the shareholders ... company also assumed the liabilities of HAI in the ...
Cached Medicine Technology:Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 2Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 3Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 4Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 5IMD Announces the Acquisition of the Kidshape® Brand 2
(Date:6/19/2013)... system for repairing damage to the genetic material DNA ... may seem, those compounds are sparking optimism as potential ... mutation in BRCA, a gene that made headlines when ... compounds, termed PARP inhibitors, are the topic of the ... & Engineering News . C&EN is the weekly news ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s ... Compressor Saver kit at an exceptional price. The 5-2-1 Compressor ... air conditioning unit during start up, saving wear and tear ... unit burn out. , The 5-2-1 Compressor Saver ... uses less power to start and drastically reduces the rush ...
(Date:6/19/2013)... Scottsdale, AZ (PRWEB) June 19, 2013 Guests ... feel healthy, wealthy and wise even if they don’t go ... that does require some early thought. , ... pockets when they take advantage of the pet-friendly Scottsdale Paradise ... Percent Package . With at least 14 days advance notice, ...
(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...
Breaking Medicine News(10 mins):Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... , THURSDAY, Aug. 11 (HealthDay News) -- The HIV ... a high prevalence of AIDS is 10 to 20 times ... government report indicates. Two percent of poor heterosexuals in ... Disease Control and Prevention researchers, analysis of National HIV Behavioral ...
... Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) has awarded ... the University Hospitals (UH) Neuromuscular Center in Northeast Ohio. ... in Cleveland, Oh., UH Ahuja Medical Center in Beachwood, ... Oh., and UH Westlake Health Center in Westlake, Oh., ...
... According to a study published in ... Society of Hematology (ASH), researchers have reported that administration ... cells from the bone marrow into the blood, is unlikely ... development of abnormalities involving loss or gains of chromosomes that ...
... -- There,s no strong evidence that taking aspirin while ... of becoming pregnant, researchers say. Routine use of ... aspirin may improve blood flow to the womb and ... cause pregnancy complications or miscarriage. To ...
... Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s disease ... according to a new study that examined the relationship ... The study included 105 Alzheimer,s patients and 125 dementia-free ... to 75 (young-old) and those 80 and older (very ...
... , THURSDAY, Aug. 11 (HealthDay News) -- The ... with a high prevalence of AIDS is 10 to 20 ... government report indicates. Two percent of poor heterosexuals ... for Disease Control and Prevention researchers, analysis of National HIV ...
Cached Medicine News:Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
... the precise requirements of blood banking ... Bank Equipment meets American Association of ... Cross (ANRC) and U.S. Food & ... freezers, and platelet incubators feature alarm ...
... Designed for the precise requirements ... Thermo Forma Blood Bank Equipment meets ... American National Red Cross (ANRC) and ... standards. Refrigerators, storage freezers, and platelet ...
... This refrigerator is specially ... of blood in standard ... Australian Standard AS3864 1997. ... air-cooled utilising CFC Free ...
Medicine Products: